EA201001691A1 - Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору - Google Patents
Антитела к гранулоцитарно-макрофагальному колониестимулирующему факторуInfo
- Publication number
- EA201001691A1 EA201001691A1 EA201001691A EA201001691A EA201001691A1 EA 201001691 A1 EA201001691 A1 EA 201001691A1 EA 201001691 A EA201001691 A EA 201001691A EA 201001691 A EA201001691 A EA 201001691A EA 201001691 A1 EA201001691 A1 EA 201001691A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- stimulating factor
- granulocyter
- colonius
- macrophagal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4852208P | 2008-04-28 | 2008-04-28 | |
| PCT/US2009/041981 WO2009134805A2 (en) | 2008-04-28 | 2009-04-28 | Antibodies to granulocyte-macrophage colony-stimulating factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201001691A1 true EA201001691A1 (ru) | 2011-10-31 |
Family
ID=41255734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201001691A EA201001691A1 (ru) | 2008-04-28 | 2009-04-28 | Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8168183B2 (https=) |
| EP (2) | EP3449941A1 (https=) |
| JP (1) | JP5688363B2 (https=) |
| KR (2) | KR101824512B1 (https=) |
| CN (1) | CN102037016B (https=) |
| AU (1) | AU2009243184B2 (https=) |
| BR (1) | BRPI0911902A2 (https=) |
| CA (1) | CA2722137C (https=) |
| CO (1) | CO6311004A2 (https=) |
| DK (1) | DK2280732T3 (https=) |
| EA (1) | EA201001691A1 (https=) |
| ES (1) | ES2704835T3 (https=) |
| IL (1) | IL208980A (https=) |
| MX (1) | MX2010011761A (https=) |
| NZ (1) | NZ588850A (https=) |
| WO (1) | WO2009134805A2 (https=) |
| ZA (1) | ZA201008028B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20081216A1 (es) | 2006-09-01 | 2008-09-04 | Therapeutic Human Polyclonals Inc | Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| WO2009134805A2 (en) | 2008-04-28 | 2009-11-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| CN102271705A (zh) * | 2008-12-22 | 2011-12-07 | 墨尔本大学 | 骨关节炎治疗 |
| CA2747206C (en) | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| WO2012012571A1 (en) | 2010-07-21 | 2012-01-26 | Hans Zassenhaus | Biolayer interferometry measurement of biological targets |
| CN103827143A (zh) | 2011-07-06 | 2014-05-28 | 莫弗系统股份公司 | 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途 |
| US9400600B2 (en) * | 2011-12-16 | 2016-07-26 | Samsung Electronics Co., Ltd. | Method, apparatus, and graphical user interface for providing visual effects on a touchscreen display |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| WO2014068029A1 (en) | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US10745475B2 (en) * | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| KR102385802B1 (ko) | 2014-05-07 | 2022-04-13 | 다케다 야쿠힝 고교 가부시키가이샤 | Gm-csf 중화 화합물을 포함하는 액체 제제 |
| SG11201802698XA (en) * | 2015-10-29 | 2018-05-30 | Hoffmann La Roche | Transgenic rabbit with common light chain |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| AU2018345751A1 (en) * | 2017-10-02 | 2020-05-07 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| CN113164520A (zh) * | 2018-09-10 | 2021-07-23 | 赫曼尼根公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
| WO2020092850A1 (en) | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| EP4054602A4 (en) | 2019-11-08 | 2023-12-06 | Mayo Foundation for Medical Education and Research | EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS |
| CN118561999B (zh) * | 2024-06-26 | 2025-03-14 | 武汉爱博泰克生物科技有限公司 | 抗人粒细胞-巨噬细胞集落刺激因子抗体、抗体对及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP2006500905A (ja) | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| EP1761561B1 (en) | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| PT2343380T (pt) * | 2004-11-16 | 2019-09-18 | Humanigen Inc | Permuta de cassetes da região variável de imunoglobulina |
| US7381802B2 (en) * | 2005-04-15 | 2008-06-03 | Universidad Nacional Autónoma De México (UNAM) | Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom |
| BRPI0608281B8 (pt) | 2005-04-18 | 2021-05-25 | Amgen Res Munich Gmbh | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende |
| RU2447085C2 (ru) * | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| US8211648B2 (en) | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
| KR20080068004A (ko) | 2005-08-15 | 2008-07-22 | 아라나 테라퓨틱스 리미티드 | 뉴 월드 영장류 구조형성영역을 가진 조작 항체 |
| US7741450B2 (en) * | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| EP2101780B1 (en) | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| EP2282757B1 (en) * | 2008-04-07 | 2013-05-22 | Kalobios Pharmaceuticals, Inc. | Neutralization of gm-csf for the treatment of heart failure |
| WO2009134805A2 (en) | 2008-04-28 | 2009-11-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
-
2009
- 2009-04-28 WO PCT/US2009/041981 patent/WO2009134805A2/en not_active Ceased
- 2009-04-28 ES ES09739607T patent/ES2704835T3/es active Active
- 2009-04-28 NZ NZ588850A patent/NZ588850A/xx not_active IP Right Cessation
- 2009-04-28 EA EA201001691A patent/EA201001691A1/ru unknown
- 2009-04-28 MX MX2010011761A patent/MX2010011761A/es active IP Right Grant
- 2009-04-28 CN CN200980118423.0A patent/CN102037016B/zh active Active
- 2009-04-28 JP JP2011507586A patent/JP5688363B2/ja active Active
- 2009-04-28 CA CA2722137A patent/CA2722137C/en active Active
- 2009-04-28 DK DK09739607.1T patent/DK2280732T3/en active
- 2009-04-28 EP EP18200356.6A patent/EP3449941A1/en not_active Ceased
- 2009-04-28 AU AU2009243184A patent/AU2009243184B2/en active Active
- 2009-04-28 EP EP09739607.1A patent/EP2280732B1/en active Active
- 2009-04-28 KR KR1020107026423A patent/KR101824512B1/ko active Active
- 2009-04-28 BR BRPI0911902A patent/BRPI0911902A2/pt not_active IP Right Cessation
- 2009-04-28 US US12/431,661 patent/US8168183B2/en active Active
- 2009-04-28 KR KR1020177023943A patent/KR101852915B1/ko active Active
-
2010
- 2010-10-28 IL IL208980A patent/IL208980A/en active IP Right Grant
- 2010-11-09 ZA ZA2010/08028A patent/ZA201008028B/en unknown
- 2010-11-25 CO CO10148019A patent/CO6311004A2/es not_active Application Discontinuation
-
2012
- 2012-04-30 US US13/460,151 patent/US9017674B2/en active Active
-
2015
- 2015-04-02 US US14/677,604 patent/US20150344565A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170126458A (ko) | 2017-11-17 |
| CA2722137C (en) | 2019-03-19 |
| US9017674B2 (en) | 2015-04-28 |
| EP2280732A2 (en) | 2011-02-09 |
| KR20110011638A (ko) | 2011-02-08 |
| MX2010011761A (es) | 2010-11-30 |
| NZ588850A (en) | 2012-12-21 |
| ZA201008028B (en) | 2012-04-25 |
| WO2009134805A3 (en) | 2010-06-03 |
| ES2704835T3 (es) | 2019-03-20 |
| US20150344565A1 (en) | 2015-12-03 |
| EP3449941A1 (en) | 2019-03-06 |
| KR101824512B1 (ko) | 2018-02-02 |
| IL208980A0 (en) | 2011-01-31 |
| AU2009243184A1 (en) | 2009-11-05 |
| US20120213776A1 (en) | 2012-08-23 |
| US20090274706A1 (en) | 2009-11-05 |
| CN102037016B (zh) | 2015-06-03 |
| US8168183B2 (en) | 2012-05-01 |
| EP2280732A4 (en) | 2012-11-14 |
| AU2009243184B2 (en) | 2015-06-04 |
| JP2011518886A (ja) | 2011-06-30 |
| WO2009134805A2 (en) | 2009-11-05 |
| BRPI0911902A2 (pt) | 2015-10-13 |
| JP5688363B2 (ja) | 2015-03-25 |
| KR101852915B1 (ko) | 2018-04-27 |
| CO6311004A2 (es) | 2011-08-22 |
| CA2722137A1 (en) | 2009-11-05 |
| EP2280732B1 (en) | 2018-10-17 |
| CN102037016A (zh) | 2011-04-27 |
| IL208980A (en) | 2015-06-30 |
| DK2280732T3 (en) | 2019-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201001691A1 (ru) | Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору | |
| CY1123739T1 (el) | Αντισωματα anti-cd38 | |
| CR20240003A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| EA201300558A1 (ru) | Соединения и способы для купирования боли | |
| EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
| SG135192A1 (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| EA201791669A2 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA201171489A1 (ru) | Аминопиримидиновые противораковые соединения | |
| WO2006058868A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| EA200700851A1 (ru) | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения | |
| EA201270575A1 (ru) | Соединения | |
| WO2010071826A3 (en) | Methods for treating osteoclast-related disease, compounds and compositions thereof | |
| GEP20115293B (en) | Isolated extract of walnuts, process for its obtaining and its use | |
| EA201300131A1 (ru) | Комбинированная фармацевтическая композиция и методы лечения заболеваний или состояний, связанных с респираторными заболеваниями или состояниями | |
| EA201100623A1 (ru) | Сульфоксиминзамещенные анилинопиримидиновые производные в качестве cdk ингибиторов, их получение и применение в качестве лекарственных средств | |
| TW200745043A (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
| CA2725873A1 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
| EP1948214A4 (en) | ANTI-TNF-ALPHA TREATMENT FOR TREATING ENTEROCOLITIS ASSOCIATED WITH IMMUNOSTIMULATORY THERAPEUTIC ANTIBODY TREATMENT | |
| EA201270116A1 (ru) | Применение лекарственной формы для наружного нанесения, содержащей хитозан | |
| CY1114760T1 (el) | Θεραπευτικη αγωγη αθηροσκληρωσης | |
| WO2010135521A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
| EA200700637A1 (ru) | Соли донепезила, подходящие для получения фармацевтических композиций |